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Abstract
Background: It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic
response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some
guidelines suggest stopping apparently ineffective therapy, but no studies have addressed this issue.
Methods: In a retrospective cohort analysis using the UK Clinical Practice Research Datalink (CPRD), we assessed
the outcome of 55,530 patients with type 2 diabetes starting their second or third non-insulin glucose-lowering
medication, with a baseline HbA1c > 58 mmol/mol (7.5%). For those with no HbA1c improvement or a limited
response at 6 months (HbA1c fall < 5.5 mmol/mol [0.5%]), we compared HbA1c 12 months later in those who
continued their treatment unchanged, switched to new treatment, or added new treatment.
Results: An increase or a limited reduction in HbA1c was common, occurring in 21.9% (12,168/55,230), who had a
mean HbA1c increase of 2.5 mmol/mol (0.2%). After this limited response, continuing therapy was more frequent (n
= 9308; 74%) than switching (n = 1177; 9%) or adding (n = 2163; 17%). Twelve months later, in those who switched
medication, HbA1c fell (− 6.8 mmol/mol [− 0.6%], 95%CI − 7.7, − 6.0) only slightly more than those who continued
unchanged (− 5.1 mmol/mol [− 0.5%], 95%CI − 5.5, − 4.8). Adding another new therapy was associated with a
substantially better reduction (− 12.4 mmol/mol [− 1.1%], 95%CI − 13.1, − 11.7). Propensity score-matched subgroups
demonstrated similar results.
Conclusions: Where glucose-lowering therapy does not appear effective on initial HbA1c testing, changing agents
does not improve glycemic control. The initial agent should be continued with another therapy added.
Keywords: Type 2 diabetes, Oral glucose-lowering medication, HbA1c, Addition, Switching, Continuation, Glycemic
control
Introduction
Current major guidelines for type 2 diabetes suggest
checking treatment response to glucose-lowering medi-
cation with an HbA1c measurement at 3 to 6 months
[1–3]. What is unclear is what to do if there is an appar-
ently poor response; should this treatment be continued
with ongoing response monitoring, should it be switched
to an alternative medication, or should another medica-
tion be added in? To date, no data from randomized
controlled trials or observational analyses are available
to address this apparently simple but clinically important
question. Despite this, national guidance in some regions
has recommended discontinuation of therapy if a re-
sponse threshold on initial HbA1c testing is not met [3].
Data from both trials and observational studies dem-
onstrate that there is a substantial amount of HbA1c
variation within individuals on stable therapy over time.
This variation produces a standard deviation (SD) of
HbA1c within individuals of around 5.0 to 7.1 mmol/
mol (0.46 to 0.65%) [4–6]. Assuming an approximately
normal distribution of HbA1c variation, one third of
people will have an HbA1c variation greater than this
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SD. As most non-insulin glucose-lowering medications
reduce HbA1c by around 11.0 mmol/mol (1.0%), with
some variation by class of therapy [7–9], there will be a
substantial proportion of people in whom the treatment
effect when starting a therapy is at least partially ob-
scured by the biological noise in HbA1c. Given this
noise, a reasonable approach to the patient who has ap-
parently had a limited initial HbA1c treatment response
might be to continue the therapy unchanged, anticipat-
ing that the true response will become apparent over
subsequent HbA1c measurements. If this hypothesis is
correct, we would expect people who switch to another
medication will have similar HbA1c outcomes compared
with those continuing the initial therapy unchanged. We
would also anticipate people adding another new therapy
will experience a greater HbA1c reduction than those
who switch despite the apparent lack of effect of the first
medication. If the lack of an initial glycemic response is
a true reflection of non-response to the new medication,
subsequent treatment switching should produce a simi-
lar response to adding another medication.
We aimed to establish whether continuing, switching,
or adding medication to an apparently ineffective
glucose-lowering therapy resulted in the greatest HbA1c
improvement.
Research design and methods
We conducted a retrospective cohort analysis of 55,530
people with type 2 diabetes starting a second or third
ever glucose-lowering medication between 2004 and
2017 inclusive. We analyzed those who had either a
worsening or a limited improvement in HbA1c (HbA1c
fall < 5.5 mmol/mol [0.5%]) 6 months after this add-
itional glucose-lowering therapy. We compared the sub-
sequent glycemic outcomes in those who continued
therapy unchanged, switched to an alternative therapy,
or added an additional agent.
Setting and participants
We identified people with type 2 diabetes within the
world’s largest longitudinal database of anonymized pri-
mary care electronic health records (EHR): the UK Clin-
ical Practice Research Datalink (CPRD) [10]. People with
type 2 diabetes were identified as previously described
[11]. In brief, people with type 2 diabetes were identified
from prescriptions of one or more glucose-lowering
therapies in the EHR consistent with a diagnosis of dia-
betes, and an age of onset of diabetes (first prescription)
over 35 years. People were considered not to have type 2
diabetes if they had any diagnosis codes suggesting ges-
tational, genetic, or secondary forms of diabetes, poly-
cystic ovarian syndrome, insulin as their first
glucose-lowering medication, or insulin within 1 year of
diagnosis. The date of diagnosis of diabetes was defined
as the earlier date of the first glucose-lowering medica-
tion prescription, first HbA1c value ≥ 48mmol/mol
(6.5%), or first diagnosis code. Where any of these oc-
curred within 3 months of registration with the patients’
practice, the diagnosis date was assumed to predate
registration and the person was excluded. We did not
put any restrictions on the date of diagnosis. An over-
view of study design and participant selection is shown
in Fig. 1.
Identification of participants with limited initial HbA1c
response to second- and third-line glucose-lowering
therapy
We assessed initial HbA1c response in participants com-
mencing second or third glucose-lowering medication (ex-
cluding insulin) between 2004 and 2017 (inclusive)
meeting the following criteria: new therapy taken continu-
ally for at least 6months (based on prescriptions issued),
pretreatment HbA1c (baseline HbA1c) > 58mmol/mol
(7.5%), a measure of post treatment HbA1c after 6 months
(initial treatment response HbA1c), ≥ 80% adherence to
all prescribed glucose-lowering therapy, and no change in
other concurrent glucose-lowering therapy. For the base-
line HbA1c, we used the most recent value measured
within the 6 months preceding the start of the new medi-
cation. We defined the initial treatment response HbA1c
as the nearest HbA1c to 6 months (± 3months) after initi-
ating the new therapy. Non-adherence was defined using
medication possession ratio of less than 80% [12–14].
We defined a limited initial response to glucose-lowering
therapy as a worsening of HbA1c or an improvement of
less than 5.5mmol/mol (0.5%). We did not examine people
with a limited response to a first ever glucose-lowering
medication as this is most commonly metformin and the
current UK guidelines advocate dose escalation rather than
treatment modification where this has occurred [3].
Participant baseline characteristics
We extracted baseline clinical characteristics at the time
of medication start: age, gender, duration of diabetes,
and body mass index (BMI), and estimated glomerular
filtration rate (eGFR). BMI and eGFR were defined using
the most recent record in the 6 months prior to the drug
start date.
Treatment choices and outcomes
From the eligible cohort, three ongoing treatment
choices were defined: continue, switch, or add. The con-
tinue group was defined as no changes to diabetes ther-
apies for an additional 12 months after the initial
treatment response HbA1c. The switch group was de-
fined as people discontinuing their first new therapy and
starting an alternative non-insulin glucose-lowering
medication within the following 12 months. The add
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group was defined as continuing their first new therapy
and adding a second non-insulin glucose-lowering medi-
cation within the following 12months. In the continue
group, the outcome HbA1c was defined as the closest
value to 12 months (± 3 months). In the switch and add
groups, the outcome HbA1c was defined as the closest
value to 6 months (± 3months) after the medication
modification. These time frames were selected to make
the follow-up period comparable across the three
groups. People without an outcome HbA1c were ex-
cluded. People with data fulfilling the inclusion criteria
for both their second and third ever medication were
Fig. 1 Flow diagram of patient inclusion and follow-up. *Patients failing to meet the criteria for continue, switch, or add had either more
complex therapy changes such as adding or switching multiple medications in the 1-year follow-up period, or had reduced adherence to any of
the study medications. †This time window was selected to provide an outcome HbA1c measurement in the same time period as the response
HbA1c in those switching or adding medications. CPRD Clinical Practice Research Datalink
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only included once, using data for their second medica-
tion only.
Statistical methods
We evaluated differences in baseline characteristics be-
tween the continue, switch, and add groups using the χ2
test for categorical variables and the unpaired t-test for
continuous data. All reported p values are two-sided.
Our primary analysis comprised examination of the
HbA1c response to continuing, switching, or adding, in
the eligible cohort, with adjustment for baseline vari-
ables using linear regression. Linear regression models
were adjusted for age, gender, duration of diabetes at the
initiation of treatment, baseline HbA1c before the first
medication, year of treatment, and line of therapy (sec-
ond or third ever medication). The response to treat-
ment choice (continue, switch, or add) is reported with
95% confidence intervals (CI) using least-square means.
Complete regression model results are also reported.
The treatment response was defined as the change in
HbA1c between the response HbA1c to their first new
therapy (measured at 6 months) and the continue,
switch, or add outcome HbA1c (defined for each group
as described above).
Subgroup and sensitivity analyses
We undertook the following subgroup analyses; separate
analysis of second- and third-line therapies, a subgroup
analysis of those with absolutely no reduction in initial
treatment response HbA1c, and subgroups of treatment
response to the most commonly modified medication
classes. In the latter subgroup analyses, we analyzed the
impact of continuing, switching, or adding after a lim-
ited response to sulfonylureas, thiazolidinediones
(TZDs), and dipeptidyl peptidase-4 (DPP4) inhibitors.
Residual confounding by characteristics influencing
treatment decision could influence the results of our pri-
mary analysis; this is particularly important for HbA1c, as
those with high HbA1c may be more likely to add therapy.
To explore this possibility, we performed a sensitivity ana-
lysis in propensity score-matched groups. Matching by
treatment choice was performed to assess the two most
clinically important comparisons: continue compared with
switch and switch compared with add. Propensity score
matching was performed using a 1:1 ratio and nearest
neighbor algorithm. A caliper for matching was set at 0.25
standard deviations [15]. Variables included in the propen-
sity matching were age, gender, duration of diabetes at the
initiation of treatment, baseline HbA1c, and HbA1c re-
sponse to the first therapy (change from the baseline
HbA1c to the initial treatment response HbA1c).
A second sensitivity analysis was performed, to explore
the possibility of confounding by medication class or line
of therapy, using the same group comparisons and
matching variables as described above but with the
addition of exact matching for first medication and second
medication (for comparison of switch and add), and for
line of therapy (i.e., if the first medication assessed was the
patients’ second ever glucose-lowering medication or their
third). An initial caliper for matching of 0.25 standard de-
viations was not sufficient to remove bias in the propen-
sity score-matched variables following the addition of the
exact matching criteria. Therefore, the matching caliper
was progressively decreased until there was no significant
difference between the matched groups (p > 0.05) for base-
line HbA1c and HbA1c response to the first therapy. This
approach is in accordance with previously published rec-
ommendations for caliper selection in 1:1 nearest neigh-
bor propensity score matching where there is a relatively
small reservoir of potential matches, whereby the aim is to
maximize the group size but minimize the risk of bias
[16].
To explore the generalizability of our results, we com-
pared the baseline characteristics of patients who were
eligible for inclusion (i.e., those with complete outcome
data and where the treatment decision met our defin-
ition for continue, switch, or add) with those starting a
new second or third medication but excluded (i.e., those
with missing outcome data for HbA1c or where the
treatment decision was more complex than a simple
continuation, switch, or add).
Results
A fifth of people starting a second or third therapy had a
limited initial HbA1c response
Within CPRD, 55,530 people with type 2 diabetes started
a new second or third glucose-lowering medication and
had complete baseline and outcome data (Fig. 1). Of these,
21.9% (12,168) had a limited HbA1c response to this new
medication in their first 6 months with a mean increase of
2.5 mmol/mol (0.2%). In people with limited response,
8939 (73.5%) continued without changes to medication,
1119 (9.2%) switched medication, and 2110 (17.3%) added
a new medication within the first year after the response
HbA1c. Those continuing therapy unchanged had older
age, longer diabetes duration, lower baseline HbA1c, and
a smaller increase in HbA1c at 6 months (Table 1). When
medication changes (switch or add) were made, it tended
to be early in the 1-year follow-up window. The mean
time to outcome HbA1c was therefore slightly longer in
the continue (12.2months; SD 2.1) compared to the
switch (10.2months; SD 4.5; p < 0.001) and add groups
(10.0 months; SD 4.5; p < 0.001).
Adding therapy led to the greatest improvement in HbA1c
After adjustment for baseline characteristics, the mean
HbA1c response to switching was slightly greater than
the response to continuing the same therapy: − 6.8
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(95%CI − 7.7, − 6.0) mmol/mol (− 0.6%) and − 5.1
(95%CI − 5.5, − 4.8) mmol/mol (− 0.5%) respectively
(Fig. 2a); (p < 0.001). Those adding additional therapy to
an apparently ineffective therapy had the greatest HbA1c re-
duction: − 12.4 (95%CI − 13.1, − 11.7) mmol/mol (− 1.1%).
Subgroup and sensitivity analyses
Similar trends were also seen in the subgroups. When
analyzed by line of therapy (Additional file 1: Appendix
1) in those who had had a limited response to their sec-
ond ever glucose-lowering medication, adding was sub-
stantially better than continuing (difference − 7.2 mmol/
mol [− 0.7%]; 95%CI − 8.0, − 6.3; p < 0.001) whereas
switching was no better (difference − 0.9 mmol/mol [−
0.1%]; 95%CI − 2.1, 0.3; p = 0.127). In those with a lim-
ited response to their third ever glucose-lowering medi-
cation, adding was also substantially better than
continuing (difference − 7.5 mmol/mol [− 0.7%]; 95%CI
− 8.8, − 6.1; p < 0.001) whereas switching was slightly
better (difference − 3.0 mmol/mol [− 0.3%]; 95%CI − 4.4,
− 1.6; p < 0.001). Restricting the analysis to only those
who had an initial worsening of their HbA1c on their
new therapy again demonstrated the same trends al-
though the improvement from the 6-month response
HbA1c was slightly greater in all groups (Additional file 1:
Appendix 2).
Propensity score-matched subgroups demonstrated a
similar HbA1c response pattern to the complete cohort
analysis (Fig. 2b and Additional file 1: Appendix 3).
Baseline characteristics of the comparison groups were
well balanced although there were some baseline differ-
ences in the medication classes used (Additional file 1:
Appendix 3). The result was unchanged when exact
matching for line of therapy and medication class was
performed (Additional file 1: Appendix 4).
We found some differences between medication clas-
ses (Fig. 3 and Additional file 1: Supplementary Appen-
dix 5): Adding therapy was better than switching or
Table 1 The characteristics of people eligible for analysis by treatment choice in the follow-up year
Continue (n = 8939) Switch (n = 1119) Add (n = 2110) p
Age at diagnosis (years) 57.4 (10.5) 54.8 (10.2) 55.3 (10.3) < 0.001
Female [n (%)] 3544 (39.6) 472 (42.2) 865 (41.0) 0.175
BMI (kg/m2) 31.5 (6.03) 33.9 (6.6) 33.5 (6.5) < 0.001
eGFR (ml/min) 77.0 (19.1) 83.4 (17.6) 82.81 (18.3) < 0.001
Diabetes duration (years) 6.2 (4.7) 5.5 (4.3) 4.9 (4.1) < 0.001
HbA1c (mmol/mol) before first new medication 69.4 (10.6) 71.9 (11.1) 72.6 (11.8) < 0.001
First new medication class [n (%)] < 0.001
Metformin 1951 (21.8) 109 (9.7) 302 (14.3)
Sulfonylureas 2594 (29.0) 203 (18.1) 772 (36.6)
TZDs 2485 (27.8) 227 (20.3) 335 (15.9)
Acarbose 127 (1.4) 24 (2.1) 18 (0.9)
Glinides 101 (1.1) 51 (4.6) 22 (1.0)
DPP4 inhibitors 1514 (16.9) 447 (39.9) 597 (28.3)
SGLT2 inhibitors 101 (1.1) 42 (3.8) 40 (1.9)
GLP1 analogues 66 (0.7) 16 (1.4) 24 (1.1)
HbA1c (mmol/mol) 6 months after first new medication 71.5 (14.4) 76.2 (15.4) 77.8 (15.4) < 0.001
Change in HbA1c at 6 months (mmol/mol)* 2.1 (8.3) 4.3 (9.8) 5.2 (10.0) < 0.001
Second new medication class [n (%)] < 0.001
Metformin N/A 25 (2.2) 62 (2.9)
Sulfonylureas N/A 243 (21.7) 627 (29.7)
TZDs N/A 248 (22.2) 621 (29.4)
Acarbose N/A 13 (1.2) 57 (2.7)
Glinides N/A 34 (3.0) 19 (0.9)
DPP4 inhibitors N/A 199 (17.8) 455 (21.6)
SGLT2 inhibitors N/A 131 (11.7) 143 (6.8)
GLP1 analogues N/A 226 (20.2) 126 (6.0)
All values are expressed as mean (SD) unless otherwise stated. *A positive change in HbA1c equates to a deterioration. BMI body mass index, eGFR estimated
glomerular filtration rate, TZD thiazolidinedione, DPP4 dipeptidyl peptidase-4, SGLT2 sodium-glucose co-transporter-2, GLP1 glucagon-like peptide-1
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continuing regardless of the original therapy showing
the limited response, but the greatest improvements in
response were seen when another therapy was added to
a TZD. Switching from an SU or TZD did not result in
improvements in response compared with continuing
the original therapy, but switching from a DPP4 did re-
sult in a significant improvement.
Participants eligible for inclusion in the study had
similar characteristics to those excluded, with statisti-
cally significant but not clinically relevant differences in
sex (40.4 vs 42.6% female in eligible vs non eligible; p <
0.001), diabetes duration (5.3 vs 5.5 years; p < 0.001), and
baseline HbA1c (73.4 vs 75.7 mmol/mol; p < 0.001)
(Additional file 1: Appendix 6).
Discussion
In our UK-representative cohort, more than a fifth of
people with complete data met our criteria for a limited
6-month response to a new therapy, demonstrating that
this is common clinical scenario. Of these, the most
common practice was to continue the same medication
over the following year (73.5%). People continuing and
switching did demonstrate a modest improvement in
HbA1c over the following year but neither approach im-
proved HbA1c much beyond the baseline HbA1c prior
to the first new therapy. Adding another new therapy to
the apparently ineffective new therapy was the only ap-
proach which led to a clinically significant improvement
in HbA1c. These findings were robust across different
approaches to analysis. For TZDs, switching was slightly
inferior to continuing therapy unchanged, and for DPP4
inhibitors, switching was substantially better than con-
tinuing. However, for each of the three classes (sulfonyl-
ureas, TZDs, and DPP4 inhibitors), adding another
medication lead to the greatest HbA1c reduction, as
found with the complete cohort. Our results therefore
demonstrate that a single HbA1c measurement cannot
be used to identify patients who have limited response
to a glucose-lowering therapy. Where a glucose-lowering
therapy does not appear to be effective, changing agents
A B C
Fig. 3 Adjusted change in HbA1c 1 year after a limited response to a sulfonylurea (n = 3569) (a), thiazolidinedione (n = 3047) (b), or DPP4
inhibitor (n = 2558) (c) stratified by the treatment decision after response HbA1c: continue, switch, or add
A B
Fig. 2 Change in HbA1c 1 year after a limited response to a new medication stratified by treatment decision after response HbA1c: continue,
switch, or add. a Adjusted HbA1c change in the complete cohort (n = 12,168). Response adjusted for age, gender, duration of diabetes, HbA1c at
initiation of the first new therapy, year of treatment, and line of therapy (second or third). b Unadjusted HbA1c in propensity score-matched
groups (n = 3351). Matched on age, gender, duration of diabetes, HbA1c at initiation of the first new therapy, and 6-month HbA1c response to
the first new therapy
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does not substantially improve glycemic control. The
initial agent should therefore be continued (where that
agent is tolerated) and additional therapy added.
The strengths of this study include our use of multiple
approaches for exploring the relationship between con-
tinuing, switching, and adding therapies, and HbA1c
outcomes in a large real-world cohort. We have found
the same trends when examined using a complete co-
hort with results adjusted for baseline characteristics
and propensity score-matched groups and in important
subgroups.
Limitations of the study include the exclusion of people
with incomplete follow-up data; while we cannot assume
generalizability to this population, their similar baseline
characteristics to those with complete follow-up data is re-
assuring. We had also insufficient numbers of people
treated with some important classes of medication to
examine the impact of continuing, switching, or adding at
a class level, e.g., sodium glucose co-transporter-2
(SGLT2) inhibitors and glucagon-like peptide-1 (GLP1)
analogues. This was predominately because they are
newer medication classes and therefore less longitudinal
data is currently available. As with all observational stud-
ies, we cannot exclude residual confounding; however, we
have used multiple methods to attempt to triangulate the
impact of treatment choices to reduce this possibility.
While we have only included participants who are adher-
ent by medication position ratio in our analysis, this does
not fully exclude differences in adherence between treat-
ment groups, as a medicine may be collected and not ac-
tually taken. A patient with side effects may be more likely
to be non-adherent and subsequently more likely to
switch therapy. However, this possibility would not explain
the glycemic benefit of adding compared with switching
that we identify, or lack of clear benefit from switching in
comparison to continuing an “ineffective” therapy. An-
other limitation of our study was that information on the
rationale for treatment decision (continue, switch, or add)
was not available from the dataset.
A tendency to continue treatment unchanged in
people who have not reached HbA1c targets (termed
clinical or treatment inertia) has been reported previ-
ously [17–19]. These data are consistent with our find-
ing that continuing a treatment in those with a
measured limited HbA1c response was the most com-
mon clinical practice. Our results suggest that a large
proportion of response variation is due to “noise”—
HbA1c variation related to diet or lifestyle change and/
or measurement error, rather than innate variation in
true “biological” response between individuals. If pa-
tients with initial worsening of HbA1c were true “non--
responders” to therapy, then switching to a different
therapy would be a much more effective strategy than
continuing the same ineffective medication. In contrast,
our results show little difference between switching ther-
apy and continuing the same medication unchanged—in
other words, these patients are obtaining underlying
glucose-lowering benefit from the medication, and the
initial lack of HbA1c improvement is substantially due
to chance variation in HbA1c caused by other,
non-treatment-related, factors. If HbA1c is repeated
without changing therapy, it will therefore improve due
to the effects of regression to the mean [20]. This is en-
tirely consistent with previous studies that show very
high variation of HbA1c on stable glucose-lowering ther-
apy [7–9]. This has implications for the study and imple-
mentation of stratified or precision approaches to
glucose-lowering therapy; while recent studies show it is
possible to predict differences in mean glucose-lowering
response by patient characteristic or biomarker status
[21–24], it may not be possible to predict a person’s re-
sponse to therapy at an individual level.
Our study is the first to examine the impact of subse-
quent treatment changes in people with an initially lim-
ited treatment response to a new glucose-lowering
therapy. A high-quality randomized trial would provide
valuable additional data to guide clinic practice in this
common scenario and may also allow assessment of
whether using multiple HbA1c measures may allow
more robust identification of poor responders to a
glucose-lowering therapy, something that is not feasible
to robustly address in this dataset due to the low fre-
quency of repeat HbA1c measurements in clinical care.
Conclusion
It is common to have a limited HbA1c response
6 months after starting a new glucose-lowering medica-
tion, but this is likely to represent non-treatment-related
HbA1c variation, rather than lack of biological response
to a therapy. Where a glucose-lowering therapy does not
appear to be effective on initial HbA1c testing, changing
agents does not improve glycemic control. The initial
agent should therefore be continued (where that agent is
tolerated) and additional therapy added.
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